Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.

Endocrinology | 2014

The dependence of prostate cancer on androgens provides a targeted means of treating advanced disease. Unfortunately, androgen deprivation therapies eventually become ineffective, leading to deadly castration-resistant prostate cancer (CRPC). One of many factors implicated in the transition to CRPC is the onset of de novo steroidogenesis. Although reactivation of steroid receptors likely plays a pivotal role in aggressive CRPC, little is understood regarding the mechanisms whereby prostate cancer cells initiate and maintain steroidogenesis. We hypothesize that steroidogenic factor 1 (SF1, NR5A1, AD4BP), a key regulator of steroidogenesis in normal endocrine tissues, is expressed in CRPC where it stimulates aberrant steroidogenesis and fuels aggressive growth. Notably, SF1 is not expressed in normal prostate tissue. Our results indicated that SF1 was absent in benign cells but present in aggressive prostate cancer cell lines. Introduction of ectopic SF1 expression in benign human prostate epithelial cells (BPH-1) stimulated increased steroidogenic enzyme expression, steroid synthesis, and cell proliferation. In contrast, data from an aggressive human prostate cancer cell line (BCaPT10) demonstrated that SF1 was required for steroid-mediated cell growth because BCaPT10 cell growth was diminished by abiraterone treatment and short hairpin RNA-mediated knockdown of SF1 (shSF1). SF1-depleted cells also exhibited defective centrosome homeostasis. Finally, whereas xenograft experiments in castrated hosts with BCaPT10 control transplants grew large, invasive tumors, BCaPT10-shSF1 knockdown transplants failed to grow. Therefore, we conclude that SF1 stimulates steroid accumulation and controls centrosome homeostasis to mediate aggressive prostate cancer cell growth within a castrate environment. These findings present a new molecular mechanism and therapeutic target for deadly CRPC.

Pubmed ID: 24265454 RIS Download

Associated grants

  • Agency: NCRR NIH HHS, United States
    Id: P51 RR000167
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000427
  • Agency: NCI NIH HHS, United States
    Id: P30 CA014520
  • Agency: NCATS NIH HHS, United States
    Id: UL1TR000427
  • Agency: NCRR NIH HHS, United States
    Id: RR000167
  • Agency: NICHD NIH HHS, United States
    Id: T32 HD041921
  • Agency: NIH HHS, United States
    Id: P51 OD011106
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK093690
  • Agency: NICHD NIH HHS, United States
    Id: 5T32-HD041921-07

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Donkey anti-goat Dylight 488 (antibody)

RRID:AB_2616594

This polyclonal targets Mouse IGG

View all literature mentions

Donkey anti-rabbit DyLight 549 (antibody)

RRID:AB_2616595

This unknown targets Rabbit IGG

View all literature mentions

bromodeoxyuridine-dmelanogaster (antibody)

RRID:AB_395993

This monoclonal targets bromodeoxyuridine

View all literature mentions

Monoclonal Anti-gamma-Tubulin antibody produced in mouse (antibody)

RRID:AB_532292

This monoclonal targets gamma-Tubulin antibody produced in mouse

View all literature mentions

goat anti-rabbit IgG-HRP (antibody)

RRID:AB_631746

This polyclonal targets goat anti-rabbit IgG-HRP

View all literature mentions

Human Nuclei (antibody)

RRID:AB_94090

This monoclonal targets ND

View all literature mentions